Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Selecting culprits in type 1 diabetes β-cell killing
Åke Lernmark
Åke Lernmark
Published December 1, 1999
Citation Information: J Clin Invest. 1999;104(11):1487-1489. https://doi.org/10.1172/JCI8826.
View: Text | PDF
Commentary

Selecting culprits in type 1 diabetes β-cell killing

  • Text
  • PDF
Abstract

Authors

Åke Lernmark

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
The peptide-binding cleft of the HLA class II molecule. The peptide is b...
The peptide-binding cleft of the HLA class II molecule. The peptide is bound by virtue of the physicochemical interaction between the cleft and the anchor residues of the peptide. The TCR contacting residues along with residues on the α1 and β1 domains (see Figure 1) determines T-cell recognition and would represent a NPPE. The molecular model was generated and kindly provided by Peter Hjelmström (for additional models, see http://depts.washington.edu/rhwlab/dq/intro.html).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts